Develops peptide and enzyme drug candidates for patients with pulmonary and fibrotic diseases, including idiopathic pulmonary fibrosis and loculated pleural effusion.
10-K for FY2025, filed Mar 26, 2026Overview and Recent DevelopmentsView ↗
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis…View ↗
LTI-03, a peptide, for which we conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker…View ↗
LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
It is developing drug candidates for people with idiopathic pulmonary fibrosis and loculated pleural effusion; it has no marketing, sales or distribution capabilities and may work with pharmaceutical and biotechnology companies to commercialize approved products.
10-K for FY2025, filed Mar 26, 2026We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis…View ↗
In May 2025, we initiated screening and recruitment of patients in the RENEW Phase 2 clinical trial of LTI-03. The RENEW trial is a Phase 2…View ↗
LTI-01 is a single chain urokinase plasminogen activator, or scuPA, for the treatment of LPE. Pleural effusion is defined by the build-up…View ↗
Sales and MarketingView ↗
We currently have no marketing, sales or distribution capabilities. In order to commercialize any products that are approved for commercial…View ↗
10-Q for Q3 FY2026, filed Nov 16, 2026
−$5.5MView ↗
8-K, filed Aug 27, 2026
Pursuant to the notice and Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has 180 days from the date of the Notice, or until…View ↗
From cancer support to pulmonary fibrosis
The older report centered on a peptide drug intended to protect cancer patients from chemotherapy side effects; the latest report centers on therapies for pulmonary and fibrotic diseases, led by a candidate for idiopathic pulmonary fibrosis.
10-K for FY2022, filed Mar 20, 2023
Competes with AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Avalyn Pharma, Vicore Pharma Holding, Endeavor BioMedicines, PureTech Health, and Roche Holding
10-K for FY2025, filed Mar 26, 2026IPF: There are currently three approved branded products for the treatment of IPF; Esbriet (pirfenidone), marketed by Roche Holding AG, and…View ↗
Loading...